Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

Shares of Viking Therapeutics VKTX have lost nearly 22% in the past six months, significantly underperforming the industry’s ...

NVO stock declines after a recent obesity study setback and intense competition from market rivals but offers long-term ...

Novo Nordisk A/S price-consensus-chart | Novo Nordisk A/S Quote Following ... in-class title for obesity treatment. The highest dose of Zepbound has shown 25% weight loss over a similar duration ...

Over the past two years rocketing sales of Wegovy and its main rival, Zepbound, have propelled the ... from $15bn this year to $94bn by 2030 (see chart 1). With hundreds of challengers eyeing ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

Learn more about where the best place to inject Zepbound is and what a typical dosing schedule looks like for the drug. You or a caregiver can inject Zepbound under the skin of your stomach or thigh.

Study participants were randomly assigned 1:1 to receive Zepbound (10mg or 15mg; maximum tolerated dose) or placebo injected subcutaneously once weekly. The primary endpoint was the change from ...

This order relates to certain FDA-approved Mounjaro and Zepbound products. The Mounjaro products are pre-filled single-dose pens (2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL ...

The FDA granted approval to Lilly’s popular obesity drug, Zepbound (tirzepatide ... CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide (2.4 mg) and semaglutide ...